Skip to main content
. Author manuscript; available in PMC: 2015 Nov 1.
Published in final edited form as: Neuropharmacology. 2014 Jul 15;86:161–173. doi: 10.1016/j.neuropharm.2014.07.006

Figure 5. Long-term exposure to CB1R or CB2R antagonists during adolescence suppresses oscillations in vitro in adult mPFC, with milder effects in SCx.

Figure 5

(A) Experimental time course. Animals were injected with the CB1R/CB2R agonist WIN (1 mg/kg) or vehicle + the CB1R antagonist AM4113 (1 mg/kg) or the CB2R antagonist AM630 (1 mg/kg) in adolescence (P35–P55) once daily for 20 days. LFPs were recorded in vitro in slices of adult mPFC (B,C) or SCx (D–F). (B,C) Cumulative probability distributions of normalized oscillation power plotted on a log scale from LFPs recorded in mPFC of adult mice treated with vehicle (solid line) or (B) AM4113 (dashed line) or (C) AM630 (dashed line) from P35–P55. KS tests compared the effect of adolescent cannabinoid treatment on normalized oscillation power. (D) Plot as in (B) of LFPs from adult SCx. (E) Plot as in (D), except normalized power was compared between animals treated with WIN or AM4113 + WIN, and between vehicle and AM4113 + WIN with KS tests. (F) Plot as in (C) of LFPs from adult SCx.